A PYMNTS Company

EU: In landmark sanction, EU fines $195M for pay-for-delay agreements

By  |  June 19, 2013

The same week the US Supreme Court ruled that drugmakers can be sued for so-called pay-for-delay agreements, the European Commission has fined nine pharmaceutical drug companies – an unprecedented sanction – for paying to keep generic drugs off the shelves. The fines, which amount to more than $195 million, follow a report by the Commission completed in 2009 which resolved that consumers paid up to 20 percent more for prescription drugs because of these agreements. Those that were fined include Denmark-based Lundbeck and India-based Ranbaxy. In a statement, European Commissioner Joaquin Almuna told reporters that the watchdog “will not tolerate such anticompetitive practices.”

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Yahoo News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.